Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy

Ikram A. Burney, Ross J. Maxwell, Stan B. Field, Cheryl L. McCoy, John R. Griffiths

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.

Original languageEnglish
Pages (from-to)367-371
Number of pages5
JournalActa Oncologica
Volume34
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Arterial Pressure
Magnetic Resonance Spectroscopy
Hydralazine
Pharmaceutical Preparations
Neoplasms
Prazosin
Calcitonin Gene-Related Peptide
Fibrosarcoma
Poisons
Vasodilator Agents
Half-Life
Fever

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy. / Burney, Ikram A.; Maxwell, Ross J.; Field, Stan B.; McCoy, Cheryl L.; Griffiths, John R.

In: Acta Oncologica, Vol. 34, No. 3, 1995, p. 367-371.

Research output: Contribution to journalArticle

Burney, Ikram A. ; Maxwell, Ross J. ; Field, Stan B. ; McCoy, Cheryl L. ; Griffiths, John R. / Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy. In: Acta Oncologica. 1995 ; Vol. 34, No. 3. pp. 367-371.
@article{085fed9ef831439ba8d004047fa9c45c,
title = "Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy",
abstract = "A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45{\%} reduction in mean arterial blood pressure (MABP) and a 40-60{\%} reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20{\%} reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20{\%} reduction in MABP led to a 50-60{\%} reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.",
author = "Burney, {Ikram A.} and Maxwell, {Ross J.} and Field, {Stan B.} and McCoy, {Cheryl L.} and Griffiths, {John R.}",
year = "1995",
doi = "10.3109/02841869509093991",
language = "English",
volume = "34",
pages = "367--371",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy

AU - Burney, Ikram A.

AU - Maxwell, Ross J.

AU - Field, Stan B.

AU - McCoy, Cheryl L.

AU - Griffiths, John R.

PY - 1995

Y1 - 1995

N2 - A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.

AB - A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.

UR - http://www.scopus.com/inward/record.url?scp=0029058639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029058639&partnerID=8YFLogxK

U2 - 10.3109/02841869509093991

DO - 10.3109/02841869509093991

M3 - Article

VL - 34

SP - 367

EP - 371

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -